UK biotech Bicycle Therapeutics has established US operations in Cambridge (MA). Rosamund Deegan, appointed to the newly established role of President and Chief Business Officer, will be responsible for leading the company’s US business development and for establishing a team in the US.

TxCell has jumped on its option for a licensing agreement with the Weizmann Institute of Science’s tech transfer arm after it was granted a far-reaching patent for redirected, genetically engineered T regulatory cells by the EPO.

Manchester University spin-out C4X Discovery Holdings plc has a new CEO. UK biotech notable Clive Dix has taken over the helm of the UK drug discovery company. Dix joined C4XD as Non-Executive Chairman in October 2014 and became Executive Chairman in November 2015.

Circassia suffered a severe blow when its cat allergy immunotherapy failed to outcompete the placebo in a Phase III trial. The company’s shares, listed in London, plunged to a third of its previous value.

After replacing several management positions over the last year, Poland’s leading generics producer Polpharma now also has a new head. Markus Sieger has succeeded Maurice Chagnaud as President of the Management Board and CEO.

CarThera’s ultrasound device opens a gate for therapeutic molecules into the brain, study shows.

Research service provider Envigo has appointed Patricia Henahan as Chief Financial Officer. She has held similar roles at Eli Lilly, AstraZeneca, Medimmune and Hospira.

With support from the Medicines for Malaria Venture and Gates Foundation, Novartis will tackle resistant malaria with a new compound.

European specialist investment firm Gilde Healthcare has closed its €250m fund for later stage and growth capital in medtech, digital health and therapeutics. The oversubscribed fund will invest in both Europe and North America.